RayKnowChina Research Map
Shortlist0

ShanghaiShanghai Jiao Tong University School of Medicine

Ruijin Hospital

上海交通大学医学院附属瑞金医院

Listed for 24 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Ruijin Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌22 papers led1 open trial led
  2. Hepatocellular carcinoma肝细胞癌35 papers led3 open trials led
  3. Stomach cancer胃癌96 papers led13 open trials led
  4. Osteosarcoma骨肉瘤13 papers led1 open trial led
  5. Gastrointestinal stromal tumour胃肠道间质瘤2 papers led
  6. Neuroblastoma神经母细胞瘤2 papers led
  7. Ewing sarcoma尤文肉瘤0 papers led
  8. Multiple myeloma多发性骨髓瘤22 papers led
  9. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病11 papers led4 open trials led
  10. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
  11. Beta thalassaemiaβ 地中海贫血0 papers led
  12. Haemophilia A血友病 A5 papers led
  13. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜0 papers led
  14. Moyamoya disease烟雾病2 papers led
  15. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎1 paper led
  16. Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led
  17. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病2 papers led
  18. Amyotrophic lateral sclerosis肌萎缩侧索硬化症2 papers led
  19. Spinal muscular atrophy脊髓性肌萎缩症0 papers led
  20. Fabry disease法布雷病3 papers led
  21. Alport syndromeAlport 综合征1 paper led
  22. IgA nephropathyIgA 肾病4 papers led2 open trials led
  23. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
  24. Familial adenomatous polyposis家族性腺瘤性息肉病2 papers led

Not listed for: Nasopharyngeal carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Aplastic anaemia, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 22 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.8%.

Papers led
22
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 3320232024: 5520242025: 992025

18 hospitals in Shanghai for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma
    Phase
    N/A
    Started
    2024-06
    Registry
    NCT06596954

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin HospitalShanghai

  2. Recruiting
    Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2023-01
    Registry
    NCT05978193

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest Hospital; 1 listed hospital as study siteShanghai

  3. Recruiting
    Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2019-09
    Registry
    NCT04135664

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest Hospital; 5 listed hospitals as study sitesNanchang, Shanghai, Tianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentRadiotherapyImmunotherapy
Departments in papersRadiation oncologyMedical oncology
Papers it led22
  1. The Clinical Value of hsa_circ_0000419 in Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma.2026Biochemical genetics
  2. Neoadjuvant camrelizumab combined with chemoradiotherapy and watch-and-wait strategy versus neoadjuvant chemoradiotherapy followed by surgery in locally advanced oesophageal squamous cell carcinoma: study protocol of a randomised controlled2025BMJ openFree full text
  3. Sparing lymphocytes during preoperative adjuvant radiotherapy for oesophageal squamous cell carcinoma (SPARE): protocol for an open-label, randomised controlled trial.2025BMJ openFree full text
  4. CT radiomics to predict pathologic complete response after neoadjuvant immunotherapy plus chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.2025European radiology
  5. Residual pattern of primary tumor and lymph node in ESCC treated with nCRT with or without pembrolizumab: an analysis from a prospective cohort.2025Frontiers in immunologyFree full text
  6. TROAP promotes esophageal squamous cell carcinoma progression via the PI3K/AKT pathway.2025Journal of cancer research and clinical oncologyFree full text
  7. Radiomics applications in the modern management of esophageal squamous cell carcinoma.2025Medical oncology (Northwood, London, England)
  8. Characterization and dosimetric predictors for absolute lymphocyte count changes during neoadjuvant chemoradiotherapy with or without pembrolizumab for esophageal squamous cell carcinoma: an analysis of a prospective cohort.2025Radiation oncology (London, England)Free full text
  9. Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2).2025Signal transduction and targeted therapyFree full text
  10. Retrospective Analysis of CT-based Habitat Analysis for Predicting pCR and Survival of ESCC Treated by Neoadjuvant Chemoradiotherapy and Esophagectomy.2025Technology in cancer research & treatmentFree full text
  11. The addition of pembrolizumab to neoadjuvant chemoradiotherapy did not increase the risk of developing postoperative anastomotic leakage for ESCC: an analysis from a prospective cohort.2024BMC cancerFree full text
  12. Integrative genomics unveils basement membrane-related diagnostic markers and therapeutic targets in esophageal squamous cell carcinoma.2024Biology directFree full text
  13. A novel computational model ITHCS for enhanced prognostic risk stratification in ESCC by correcting for intratumor heterogeneity.2024Briefings in bioinformaticsFree full text
  14. Real-world evaluation of multimodal treatment practice in older oesophageal cancer patients.2024European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  15. A machine learning approach using 18F-FDG PET and enhanced CT scan-based radiomics combined with clinical model to predict pathological complete response in ESCC patients after neoadjuvant chemoradiotherapy and anti-PD-1 inhibitors.2024Frontiers in immunologyFree full text
  16. Robotic Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer: A Meta-analysis.2023Annals of surgery
  17. High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy.2023Journal for immunotherapy of cancerFree full text
  18. Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort.2023Thoracic cancerFree full text
  19. Comment on "Toxic epidermal necrolysis during camrelizumab treatment for oesophageal squamous cell carcinoma".2022Contact dermatitis
  20. Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).2022Future oncology (London, England)
  21. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1).2021European journal of cancer (Oxford, England : 1990)
  22. Beclin-1 is a Promising Prognostic Biomarker in a Specific Esophageal Squamous Cell Carcinoma Population.2021Pathology oncology research : PORFree full text
All its trials on ClinicalTrials.gov, any status11
  1. Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell CarcinomaRecruitingNCT06596954Lead sponsorN/AStart 2024-06
  2. Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell CarcinomaStatus unknownNCT06122493Lead sponsorPhase 2Start 2022-11
  3. Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell CarcinomaCompletedNCT04435197Lead sponsorPhase 2Start 2020-08
  4. Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of EsophagusCompletedNCT03792347Lead (inferred)Phase 1Start 2019-01
  5. Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell CarcinomaRecruitingNCT05978193Study sitePhase 2Start 2023-01
  6. Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell CarcinomaRecruitingNCT04135664Study sitePhase 3Start 2019-09
  7. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Study sitePhase 2Start 2022-10
  8. Robot-assisted Esophagectomy Versus Conventional Thoracoscopic EsophagectomyStatus unknownNCT03094351Study sitePhase 3Start 2017-07
  9. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyCompletedNCT03933449Study sitePhase 3Start 2016-12
  10. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)CompletedNCT02649361Study sitePhase 2Start 2016-01
  11. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02611700Study sitePhase 3Start 2015-11
More papers found outside PubMed (not counted)21
  1. Association of Skeletal Muscle and Adiposity Measured by Computed Tomography with Toxicity and pCR in Esophageal Squamous Cell Carcinoma Receiving Standardized Neoadjuvant Chemoradiotherapy2025International Journal of Radiation Oncology*Biology*Physicsarticle
  2. The Predictive Value of Pretreatment Peripheral T-Lymphocyte Subsets for Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma Patients Undergoing Neoadjuvant Chemoradiotherapy: A Prospective Cohort Analysis2025International Journal of Radiation Oncology*Biology*Physicsarticle
  3. Abstract CT213: Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C2024Cancer Researchconference-abstract
  4. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C.2024Journal of Clinical Oncologyconference-abstract
  5. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C.2024Journal of Clinical Oncologyconference-abstract
  6. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from multi-cohort, multi-center phase II trial ALTER-G-001-cohort A.2024Journal of Clinical Oncologyconference-abstract
  7. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncologyconference-abstract
  8. First Exploration of the Characterization and Dosimetric Predictors for Absolute Lymphocyte Count Changes during nCRT with or without Pembrolizumab for Esophageal Squamous Cell Carcinoma: An Analysis of a Prospective Cohort2024International Journal of Radiation Oncology*Biology*Physicsarticle
  9. 103P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A2023Annals of Oncologyarticle
  10. 150P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C2023Annals of Oncologyarticle
  11. 1628P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)2023Annals of Oncologyarticle
  12. A propensity score–matched analysis to evaluate the benefit of adjuvant therapy on disease progression of esophageal squamous cell carcinoma after R0 esophagectomy.2023Journal of Clinical Oncologyconference-abstract
  13. Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway2023Figsharedataset
  14. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Results from a multi-cohort, multicenter phase II trial (ALTER-G-001).2023Journal of Clinical Oncologyconference-abstract
  15. P-104 Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)2023Annals of Oncologyconference-abstract
  16. Prediction of Response to Neoadjuvant Chemoradiotherapy Combined with Pembrolizumab in Esophageal Squamous Cell Carcinoma with CT/FDG PET Radiomic Signatures Based on Machine Learning Classification2023International Journal of Radiation Oncology*Biology*Physicsarticle
  17. Sarcopenia as a Predictor of Neoadjuvant Therapy-Related Toxicity in Esophageal Squamous Cell Carcinoma Patients2023International Journal of Radiation Oncology*Biology*Physicsarticle
  18. Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: A multicenter, multicohort clinical trial (ALTER-G-001).2022Journal of Clinical Oncologyconference-abstract
  19. Exosomes-derived miR-154-5p attenuates esophageal squamous cell carcinoma progression and angiogenesis by targeting kinesin family member 142022Figsharedataset
  20. Postoperative Radiotherapy Involving Tumor Bed with or without Elective Nodal Irradiation in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Center, Prospective Randomized Phase II Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  21. Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma2021Annals of Surgeryarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 35 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
35
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 7720212022: 6620222023: 5520232024: 9920242025: 772025

15 hospitals in Shanghai for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07331883

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin Hospital; 2 listed hospitals as study sitesChangchun, Shanghai

  2. Recruiting
    The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06746194

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  3. Recruiting
    Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
    Phase
    Not given
    Started
    2023-03
    Registry
    NCT05870969

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  4. Recruiting
    JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06954467

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Harbin, Hefei, Nanchang, Shanghai, Shenyang, Zhengzhou

  5. Not yet recruiting
    29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07100236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wenzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionHepatitis B & cirrhosis
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicinePathology / laboratory medicineMedical oncology

Over half of these papers are lab or animal studies.

Papers it led35
  1. RIPPLY1 suppresses cancer cell stemness via targeting TBX19 in CTNNB1 -mutated hepatocellular carcinoma.2026Hepatology (Baltimore, Md.)
  2. Radiomics with Machine Learning Improves the Prediction of Microscopic Peritumoral Small Cancer Foci and Early Recurrence in Hepatocellular Carcinoma.2025Academic radiology
  3. Suppression of pseudogene MT2P1 transcription induced by E2F7 inhibits hepatocellular carcinoma cell proliferation and facilitates apoptosis via preserving its parental gene.2025Cancer biology & therapyFree full text
  4. Ascending E2F7a/b ratio facilitates KLF13 transcription in hepatocellular carcinoma and correlates with the abundance of binuclear hepatocytes (ABH) modulation for short-term recurrence.2025FASEB journal : official publication of the Federation of American Societies for Experimental BiologyFree full text
  5. Single-Gene Mutations in Hepatocellular Carcinoma: Applications and Challenges in Precision Medicine.2025International journal of medical sciencesFree full text
  6. Preoperative Multifrequency MR Elastography for Stratifying Wnt/β-Catenin Pathway and Microvascular Invasion Phenotypes in Hepatocellular Carcinoma.2025Journal of magnetic resonance imaging : JMRIFree full text
  7. Paracancerous binuclear hepatocytes assessed by computer program is a novel biomarker for short term recurrence of hepatocellular carcinoma after surgery.2025Scientific reportsFree full text
  8. A Nanoplatform of Reversing Tumor Immunosuppressive Microenvironment Based on the NIR-II Gold Hollow Nanorod for the Treatment of Hepatocellular Carcinoma.2025Small (Weinheim an der Bergstrasse, Germany)
  9. Interim analysis of the PARADISE study: Benefits of add-on peginterferon-α in NA-treated patients with CHB.2024Antiviral researchRCT
  10. Astragaloside IV inhibits cell viability and glycolysis of hepatocellular carcinoma by regulating KAT2A-mediated succinylation of PGAM1.2024BMC cancerFree full text
  11. The prognostic and antitumor roles of key genes of ferroptosis in liver hepatocellular cancer and stomach adenocarcinoma.2024Cancer biomarkers : section A of Disease markersFree full text
  12. FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study.2024Frontiers in immunologyFree full text
  13. METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation.2024Journal of hematology & oncologyFree full text
  14. Three-Dimensional Multifrequency MR Elastography for Microvascular Invasion and Prognosis Assessment in Hepatocellular Carcinoma.2024Journal of magnetic resonance imaging : JMRI
  15. Risk predictive model for the development of hepatocellular carcinoma before initiating long-term antiviral therapy in patients with chronic hepatitis B virus infection.2024Journal of medical virology
  16. Alternative splicing-related long noncoding RNA ANRIL facilitates hepatocellular carcinoma by targeting the miR-199a-5p/SRSF1 axis and impacting Anillin.2024Molecular carcinogenesis
  17. Incidence rates of hepatocellular carcinoma based on risk stratification in steatotic liver disease for precision medicine: A real-world longitudinal nationwide study.2024PLoS medicineFree full text
  18. Silencing of KNTC1 inhibits hepatocellular carcinoma cells progression via suppressing PI3K/Akt pathway.2023Cellular signalling
  19. Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma.2023Clinical and experimental medicineFree full text
  20. Attenuation of binuclear hepatocytes in the paracancerous liver tissue is associated with short-term recurrence of hepatocellular carcinoma post-radical surgery.2023FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  21. Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma.2023Journal of advanced researchFree full text
  22. Editorial for "LI-RADS Category on MRI Is Associated With Recurrence of Intrahepatic Cholangiocarcinoma After Surgery: A Multicenter Study".2023Journal of magnetic resonance imaging : JMRI
  23. Pseudogene UBE2MP1 derived transcript enhances in vitro cell proliferation and apoptosis resistance of hepatocellular carcinoma cells through miR-145-5p/RGS3 axis.2022AgingFree full text
  24. Circular RNA circ SET domain containing 2 (circSETD2) inhibits hepatocellular carcinoma cell proliferation and invasion in vivo and in vitro.2022BioengineeredFree full text
  25. Overexpressed Histocompatibility Minor 13 was Associated with Liver Hepatocellular Carcinoma Progression and Prognosis.2022Genetics researchFree full text
  26. PITX2C increases the stemness features of hepatocellular carcinoma cells by up-regulating key developmental factors in liver progenitor.2022Journal of experimental & clinical cancer research : CRFree full text
  27. E2F7 enhances hepatocellular carcinoma growth by preserving the SP1/SOX4/Anillin axis via repressing miRNA-383-5p transcription.2022Molecular carcinogenesisFree full text
  28. Pseudogene SNRPFP1 derived long non-coding RNA facilitates hepatocellular carcinoma progress in vitro by sponging tumor-suppressive miR-126-5p.2022Scientific reportsFree full text
  29. Identification of prognostic long non-coding RNA signature with potential drugs in hepatocellular carcinoma.2021AgingFree full text
  30. Immunological effect of irreversible electroporation on hepatocellular carcinoma.2021BMC cancerFree full text
  31. Identification of Key Biological Processes, Pathways, Networks, and Genes with Potential Prognostic Values in Hepatocellular Carcinoma Using a Bioinformatics Approach.2021Cancer biotherapy & radiopharmaceuticals
  32. PHF19 activates hedgehog signaling and promotes tumorigenesis in hepatocellular carcinoma.2021Experimental cell research
  33. ACTN1 supports tumor growth by inhibiting Hippo signaling in hepatocellular carcinoma.2021Journal of experimental & clinical cancer research : CRFree full text
  34. Feasibility of automatic detection of small hepatocellular carcinoma (≤2 cm) in cirrhotic liver based on pattern matching and deep learning.2021Physics in medicine and biology
  35. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases.2021TheranosticsFree full text
Chinese-language papers (not in the count)3
  1. [Value of albumin RNAscope in situ hybridization in diagnosis and differential diagnosis of hepatocellular carcinoma].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Standardized screening and early imaging diagnosis strategies for hepatocellular carcinoma].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  3. [Risk assessment and management of hepatocellular carcinoma occurrence in patients with chronic hepatitis B in the era of antiviral therapy].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status11
  1. Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)RecruitingNCT07331883Lead sponsorPhase 2Start 2025-11
  2. The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor TherapyRecruitingNCT06746194Lead sponsorStart 2024-12
  3. Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)RecruitingNCT05870969Lead sponsorStart 2023-03
  4. Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated CirrhosisStatus unknownNCT04160897Lead (inferred)Start 2019-10
  5. 29-Gene Liver Cancer Subtype and Immunotherapy EffectivenessNot yet recruitingNCT07100236Study siteStart 2025-08
  6. JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular CarcinomaRecruitingNCT06954467Study sitePhase 2Start 2025-05
  7. Pembrolizumab and Lenvatinib for Resectable Hepatocellular CarcinomaStatus unknownNCT05389527Study sitePhase 2Start 2022-09
  8. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/BevActive, not recruitingNCT04649489Study sitePhase 3Start 2021-04
  9. Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma PatientsStatus unknownNCT05343832Study siteStart 2021-11
  10. To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver CancerTerminatedNCT04520906Study siteN/AStart 2020-12
  11. A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB PatientsStatus unknownNCT05671315Study siteN/AStart 2019-07

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 96 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 1.0%.

Papers led
96
2021–2025
Trials led
31
any status, ClinicalTrials.gov
Open trials led
13
recruiting or about to
Open trials as a site
10
led by another institution
Papers led per year
2021: 141420212022: 242420222023: 171720232024: 202020242025: 21212025

18 hospitals in Shanghai for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 23

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07556640

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  2. Recruiting
    Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT06519591

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  3. Recruiting
    IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Registry
    NCT07025889

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  4. Recruiting
    Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07026149

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  5. Recruiting
    Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07366528

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin Hospital; 3 listed hospitals as study sitesShanghai

  6. Recruiting
    Predicting Efficacy of Preoperative Immunotherapy in Advanced Gastric Cancer
    Phase
    Not given
    Started
    2025-06
    Registry
    NCT07824479

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin HospitalShanghai

  7. Recruiting
    Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT07867392

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  8. Recruiting
    The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
    Phase
    Not given
    Started
    2024-06
    Registry
    NCT06597526

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  9. Recruiting
    Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer
    Phase
    N/A
    Started
    2020-09
    Registry
    NCT05140746

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  10. Not yet recruiting
    Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging
    Phase
    Not given
    Started
    2026-04
    Registry
    NCT07554742

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  11. Not yet recruiting
    GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
    Phase
    Phase 1
    Started
    2026-11
    Registry
    NCT07923396

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  12. Not yet recruiting
    Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06888037

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  13. Not yet recruiting
    Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
    Phase
    Phase 3
    Started
    2021-09
    Registry
    NCT04384601

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin HospitalShanghai

  14. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  15. Recruiting
    A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06901531

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Shanghai, Shijiazhuang, Tianjin, Wuhan, Zhengzhou

  16. Recruiting
    Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer:MetBio-CRC
    Phase
    Not given
    Started
    2025-06
    Registry
    NCT07068529

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  17. Recruiting
    Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer:MetBio-GC
    Phase
    Not given
    Started
    2025-06
    Registry
    NCT07076979

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  18. Recruiting
    DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
    Phase
    Phase 2/Phase 3
    Started
    2024-02
    Registry
    NCT06221748

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Harbin, Jinan, Kunming, Qingdao, Shanghai, Wuhan, Xiamen, Xuzhou, Zhengzhou

  19. Recruiting
    Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06679244

    Age 18 years to 80 years (registered criteria)

    Led by Huashan Hospital; 2 listed hospitals as study sitesShanghai

  20. Recruiting
    Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2023-04
    Registry
    NCT05918094

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 6 listed hospitals as study sitesChengdu, Guangzhou, Harbin, Nanchang, Shanghai, Wuhan, Zhengzhou

  21. Recruiting
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT06035250

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou

  22. Recruiting
    A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
    Phase
    Phase 1
    Started
    2022-06
    Registry
    NCT05365581

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai, Wuhan, Zhengzhou

  23. Not yet recruiting
    Prospective Assessment of Alignment Between Multimodal Artificial Intelligence and Multidisciplinary Team Decisions in Gastrointestinal Oncology
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07746830

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseChemotherapy & combined treatmentImaging & AI
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyRadiology / nuclear medicinePathology / laboratory medicine
Papers it led96
  1. Super-enhancer Activates Master Transcription Factor NR3C1 Expression and Promotes 5-FU Resistance in Gastric Cancer.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Lenvatinib Plus Paclitaxel as Second-Line Therapy for Advanced Gastric Cancer Patients: A Dose Escalation Exploratory Study.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. Machine Learning-Driven SERS Analysis Platform for Accurate and Rapid Diagnosis of Peritoneal Metastasis from Gastric Cancer.2025Annals of surgical oncology
  4. Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immuno2025BMC cancerFree full text
  5. Loss of DRD5P2 in hypoxia attenuates Rock2 degradation to promote EMT and gastric cancer metastasis.2025Biochimica et biophysica acta. Molecular basis of disease
  6. USP4-Mediated deubiquitination of A2AR suppresses autophagy-dependent ferroptosis in gastric cancer.2025Cellular and molecular life sciences : CMLSFree full text
  7. Deciphering of intra-tumoural heterogeneity and the interplay between metastasis-associated meta-program and myofibroblasts in gastric cancer.2025Clinical and translational medicineFree full text
  8. Prediction of tumor regression grade in far-advanced gastric cancer after preoperative immuno-chemotherapy using dual-energy CT-derived extracellular volume fraction.2025European radiology
  9. Clinical and body composition parameters as predictors of response to chemotherapy plus PD-1 inhibitor in gastric cancer.2025Frontiers in immunologyFree full text
  10. Predictive value of label-free surface-enhanced Raman spectroscopy for locally advanced gastric cancer following neoadjuvant chemoimmunotherapy.2025Frontiers in immunologyFree full text
  11. Gallstones, cholecystectomy, and cancer risk: an observational and Mendelian randomization study.2025Frontiers of medicine
  12. Asian consensus on normothermic intraperitoneal and systemic treatment for gastric cancer with peritoneal metastasis.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  13. Resveratrol targets mitochondrial USP36-SOD2 to induce autophagy-ferroptosis and inhibit gastric cancer progression.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  14. FLOT vs DOS neoadjuvant chemotherapy in locally advanced gastric cancer: propensity score analysis.2025International journal of clinical oncology
  15. SIGLEC11 promotes M2 macrophage polarization through AKT-mTOR signaling and facilitates the progression of gastric cancer.2025Journal for immunotherapy of cancerFree full text
  16. Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05).2025Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCTFree full text
  17. Malignant gastric glomus tumor with heterochronous liver metastases: a case report and review of the literature.2025Journal of medical case reportsFree full text
  18. Multi-Omics Analysis Reveals OBSCN as a Key Modulator of Tumor Microenvironment, Microbial Signatures and Clinical Outcomes in Gastric Cancer.2025MicrobiologyOpenFree full text
  19. Raman spectroscopy analysis combined with computed tomography imaging to identify microsatellite instability in gastric cancers.2025Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  20. Overlap Versus π-Shaped Esophagojejunostomy After Laparoscopic Total Gastrectomy for Gastric Cancer: A Comparative Study.2025Surgical laparoscopy, endoscopy & percutaneous techniques
  21. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in gastric adenosquamous carcinoma.2025Virchows Archiv : an international journal of pathologyFree full text
  22. The efficacy of neoadjuvant chemotherapy is different for type 4 and large type 3 gastric cancer.2024American journal of surgery
  23. Improving diagnosis and outcome prediction of gastric cancer via multimodal learning using whole slide pathological images and gene expression.2024Artificial intelligence in medicine
  24. The prognostic and antitumor roles of key genes of ferroptosis in liver hepatocellular cancer and stomach adenocarcinoma.2024Cancer biomarkers : section A of Disease markersFree full text
  25. PHF10 inhibits gastric epithelium differentiation and induces gastric cancer carcinogenesis.2024Cancer gene therapyFree full text
  26. Drug-induced senescence by aurora kinase inhibitors attenuates innate immune response of macrophages on gastric cancer organoids.2024Cancer lettersFree full text
  27. The effect of self-designed metabolic equivalent exercises on cancer-related fatigue in patients with gastric cancer: A randomized controlled trial.2024Cancer medicineRCTFree full text
  28. SLC7A9 suppression increases chemosensitivity by inducing ferroptosis via the inhibition of cystine transport in gastric cancer.2024EBioMedicineFree full text
  29. In-hospital outcomes of older patients with gastric cancer and their risk factors: large comprehensive institution-based study.2024European geriatric medicine
  30. Perioperative systemic and prophylactic intraperitoneal chemotherapy for type 4/large type 3 gastric cancer: DRAGON-10.2024Future oncology (London, England)Free full text
  31. Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  32. Comprehensive multi-omics analysis and experimental verification reveal PFDN5 is a novel prognostic and therapeutic biomarker for gastric cancer.2024Genomics
  33. Cytotoxic effects of NIR responsive chitosan-polymersome layer coated melatonin-upconversion nanoparticles on HGC27 and AGS gastric cancer cells: Role of the ROS/PI3K/Akt/mTOR signaling pathway.2024International journal of biological macromolecules
  34. Blocking EGR1/TGF-β1 and CD44s/STAT3 Crosstalk Inhibits Peritoneal Metastasis of Gastric Cancer.2024International journal of biological sciencesFree full text
  35. GC-CDSS: Personalized gastric cancer treatment recommendations system based on knowledge graph.2024International journal of medical informatics
  36. Value of 68Ga-FAPI-04 and 18F-FDG PET/CT in Early Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.2024Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  37. Paired organoids from primary gastric cancer and lymphatic metastasis are useful for personalized medicine.2024Journal of translational medicineFree full text
  38. Development of Aptamer-DNAzyme based metal-nucleic acid frameworks for gastric cancer therapy.2024Nature communicationsFree full text
  39. Tumor-mesothelium HOXA11-PDGF BB/TGF β1-miR-181a-5p-Egr1 feedforward amplifier circuity propels mesothelial fibrosis and peritoneal metastasis of gastric cancer.2024OncogeneFree full text
  40. VPS35 promotes gastric cancer progression through integrin/FAK/SRC signalling-mediated IL-6/STAT3 pathway activation in a YAP-dependent manner.2024OncogeneFree full text
  41. Latest guideline of endoscopic submucosal dissection of early gastric cancer may not be suitable for Chinese patients: retrospective study findings from two centers.2024Surgical endoscopyFree full text
  42. CT-Based Radiomic Score: A Risk Stratifier in Far-Advanced Gastric Cancer Patients.2023Academic radiologyRCT
  43. Efficacy and prognostic value of delta radiomics on dual-energy computed tomography for gastric cancer with neoadjuvant chemotherapy: a preliminary study.2023Acta radiologica (Stockholm, Sweden : 1987)RCT
  44. BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C-MYC/PLCG1/Perk Axis.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  45. Androgen receptor promotes cell stemness via interacting with co-factor YAP1 in gastric cancer.2023Biochemical pharmacology
  46. The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.2023Cancer medicineFree full text
  47. HNF4A-BAP31-VDAC1 axis synchronously regulates cell proliferation and ferroptosis in gastric cancer.2023Cell death & diseaseFree full text
  48. VPS35 promotes cell proliferation via EGFR recycling and enhances EGFR inhibitors response in gastric cancer.2023EBioMedicineFree full text
  49. Utility of [68Ga]FAPI-04 and [18F]FDG dual-tracer PET/CT in the initial evaluation of gastric cancer.2023European radiologyFree full text
  50. Sintilimab combined neoadjuvant intraperitoneal and systemic chemotherapy in gastric cancer with peritoneal metastasis.2023Future oncology (London, England)
  51. Exosomal hsa-let-7g-3p and hsa-miR-10395-3p derived from peritoneal lavage predict peritoneal metastasis and the efficacy of neoadjuvant intraperitoneal and systemic chemotherapy in patients with gastric cancer.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  52. Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP signaling.2023International journal of biological sciencesFree full text
  53. A combined radiomic model distinguishing GISTs from leiomyomas and schwannomas in the stomach based on endoscopic ultrasonography images.2023Journal of applied clinical medical physicsFree full text
  54. Paracrine activin B-NF-κB signaling shapes an inflammatory tumor microenvironment in gastric cancer via fibroblast reprogramming.2023Journal of experimental & clinical cancer research : CRFree full text
  55. Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer.2023Matrix biology : journal of the International Society for Matrix Biology
  56. Intra-abdominal fat volume estimation by multi-detector rows computed tomography: relevance in surgical fellowship training program in Shanghai: a retrospective study.2023PeerJFree full text
  57. Cancer-associated fibroblasts impair the cytotoxic function of NK cells in gastric cancer by inducing ferroptosis via iron regulation.2023Redox biologyFree full text
  58. Euclidean distance-based Raman spectroscopy (EDRS) for the prognosis analysis of gastric cancer: A solution to tumor heterogeneity.2023Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  59. CPT1C promotes the potential of gastric cancer ovarian metastasis through up-regulating fatty acid oxidation.2022Acta biochimica et biophysica SinicaFree full text
  60. Long non-coding RNA NUT family member 2A-antisense RNA 1 sponges microRNA-613 to increase the resistance of gastric cancer cells to matrine through regulating oxidative stress and vascular endothelial growth factor A.2022AgingFree full text
  61. A Modified Billroth-II with Braun Anastomosis in Totally Laparoscopic Distal Gastrectomy: Initial Experience Compared with Roux-en-Y Anastomosis.2022Annals of surgical oncology
  62. Initial screening of gastric cancer using oral contrast-enhanced trans-abdominal ultrasonography in rural asymptomatic individuals.2022Cancer epidemiology
  63. LncRNA LENGA acts as a tumor suppressor in gastric cancer through BRD7/TP53 signaling.2022Cellular and molecular life sciences : CMLSFree full text
  64. CRISPR/Cas9-mediated knockout of SGLT1 inhibits proliferation and alters metabolism of gastric cancer cells.2022Cellular signalling
  65. Prognostic role of iodine values for gastric cancer after neoadjuvant chemotherapy: a strong independent prognostic factor.2022Diagnostic and interventional radiology (Ankara, Turkey)Free full text
  66. Endoscopic closure of a large gastric mucosal defect after endoscopic submucosal dissection using a novel endoscopic string-with-knotter suture device.2022Endoscopy
  67. Evaluation of dual-energy CT derived radiomics signatures in predicting outcomes in patients with advanced gastric cancer after neoadjuvant chemotherapy.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  68. CHRDL2 promotes cell proliferation by activating the YAP/TAZ signaling pathway in gastric cancer.2022Free radical biology & medicine
  69. Identification of prognostic gene expression signatures based on the tumor microenvironment characterization of gastric cancer.2022Frontiers in immunologyFree full text
  70. Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies.2022Frontiers in immunologyFree full text
  71. Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer.2022Future oncology (London, England)
  72. A phase II study of perioperative treatment in gastric cancer with No.16a2/b1 lymph node metastasis: DRAGON-06 trial.2022Future oncology (London, England)
  73. Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).2022Future oncology (London, England)
  74. A phase III trial of neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis.2022Future oncology (London, England)
  75. Atranorin driven by nano materials SPION lead to ferroptosis of gastric cancer stem cells by weakening the mRNA 5-hydroxymethylcytidine modification of the Xc-/GPX4 axis and its expression.2022International journal of medical sciencesFree full text
  76. Application Value of 4K High-Definition System in Laparoscopic Gastrectomy: Preliminary Results and Initial Experience.2022Journal of laparoendoscopic & advanced surgical techniques. Part A
  77. Molecular evolutionary process of advanced gastric cancer during sequential chemotherapy detected by circulating tumor DNA.2022Journal of translational medicineFree full text
  78. The dynamic alteration of transcriptional regulation by crucial TFs during tumorigenesis of gastric cancer.2022Molecular medicine (Cambridge, Mass.)Free full text
  79. Pangenomic analysis of Chinese gastric cancer.2022Nature communicationsFree full text
  80. A Novel Glycolysis-Related Long Noncoding RNA Signature for Predicting Overall Survival in Gastric Cancer.2022Pathology oncology research : PORFree full text
  81. An xception model based on residual attention mechanism for the classification of benign and malignant gastric ulcers.2022Scientific reportsFree full text
  82. Quantifying the cell morphology and predicting biological behavior of signet ring cell carcinoma using deep learning.2022Scientific reportsFree full text
  83. Assessment of liver metastases radiomic feature reproducibility with deep-learning-based semi-automatic segmentation software.2021Acta radiologica (Stockholm, Sweden : 1987)
  84. Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases.2021BMC cancerFree full text
  85. A greater lymph node yield is required during pathological examination in microsatellite instability-high gastric cancer.2021BMC cancerFree full text
  86. LncRNA MALAT1 promotes gastric cancer progression via inhibiting autophagic flux and inducing fibroblast activation.2021Cell death & diseaseFree full text
  87. Identification of ARGLU1 as a potential therapeutic target for gastric cancer based on genome-wide functional screening data.2021EBioMedicineFree full text
  88. ATP5B promotes the metastasis and growth of gastric cancer by activating the FAK/AKT/MMP2 pathway.2021FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  89. A randomized controlled trial to evaluate omentum-preserving gastrectomy for patients with T1-T3 gastric cancer.2021Future oncology (London, England)
  90. YY1-modulated long non-coding RNA SNHG12 promotes gastric cancer metastasis by activating the miR-218-5p/YWHAZ axis.2021International journal of biological sciencesFree full text
  91. Staged laparoscopic management of locally advanced gastric cancer with outlet obstruction.2021Journal of surgical oncology
  92. Impact of microsatellite status on negative lymph node count and prognostic relevance after curative gastrectomy.2021Journal of surgical oncology
  93. The Validity of the GLIM Criteria for Malnutrition in Hospitalized Patients with Gastric Cancer.2021Nutrition and cancer
  94. Comprehensive Analysis of Ferroptosis-Related Markers for the Clinical and Biological Value in Gastric Cancer.2021Oxidative medicine and cellular longevityFree full text
  95. Collective dynamics of gastric cancer cells in fluid.2021Physical review. E
  96. The cross-talk between tumor cells and activated fibroblasts mediated by lactate/BDNF/TrkB signaling promotes acquired resistance to anlotinib in human gastric cancer.2021Redox biologyFree full text
Chinese-language papers (not in the count)14
  1. [Current status and prospects of minimally invasive surgical treatment for gastric cancer].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Strategies for supra-pancreatic lymph node dissection in laparoscopic gastric cancer surgery].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Clinical application of intraperitoneal chemotherapy ports in patients with gastric cancer and peritoneal metastases].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Clinical value and implementation strategies of normothermic intraperitoneal and systemic chemotherapy (NIPS) in the treatment of gastric cancer with peritoneal metastasis].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Key measures to improve the efficacy of diagnosis and treatment of gastric cancer with peritoneal metastasis].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. [Analysis of discordant results between multiplex fluorescence PCR-capillary electrophoresis for microsatellite instability (MSI) detection and immunohistochemistry (IHC) for mismatch repair (MMR) protein expression in gastrointestinal aden2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
  7. [Clinical significance of combined therapy with immune checkpoint inhibitor in perioperative treatment for locally advanced gastric cancer or adenocarcinoma of gastroesophageal junction].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [Clinical significance of immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer].2024Zhonghua yi xue za zhi
  9. [Preliminary analysis of the promotion effect of laparoscopic standardized surgical treatment for gastric cancer in regional medical centers in Shanghai].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  10. [Small steps to thousands of miles: a tribute to Chinese laparoscopic gastric cancer surgery].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  11. [Digestive tract reconstruction after laparoscopic proximal gastrectomy for adenocarcinoma of esophagogastric junction].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  12. [Strategies of chemotherapy for peritoneal metastasis of gastrointestinal cancer].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  13. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  14. [Current status and prospect of perioperative therapy for locally advanced gastric cancer].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status58
  1. GK01 Cell Therapy in Gastric Cancer With Peritoneal MetastasisNot yet recruitingNCT07923396Lead sponsorPhase 1Start 2026-11
  2. LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory StudyRecruitingNCT07556640Lead sponsorPhase 2Start 2026-04
  3. Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET ImagingNot yet recruitingNCT07554742Lead sponsorStart 2026-04
  4. Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric CancerNot yet recruitingNCT06888037Lead sponsorPhase 2Start 2025-03
  5. Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction CancerRecruitingNCT07867392Lead sponsorPhase 2Start 2025-02
  6. Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric CancerRecruitingNCT07026149Lead sponsorPhase 2Start 2025-06
  7. IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric CancerRecruitingNCT07025889Lead sponsorPhase 1/Phase 2Start 2025-06
  8. Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric CancerRecruitingNCT07366528Lead sponsorPhase 3Start 2025-12
  9. Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal MetastasisRecruitingNCT06519591Lead sponsorPhase 2Start 2025-02
  10. Predicting Efficacy of Preoperative Immunotherapy in Advanced Gastric CancerRecruitingNCT07824479Lead sponsorStart 2025-06
  11. The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.RecruitingNCT06597526Lead sponsorStart 2024-06
  12. Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric CancerNot yet recruitingNCT04384601Lead sponsorPhase 3Start 2021-09
  13. Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric CancerRecruitingNCT05140746Lead sponsorN/AStart 2020-09
  14. Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric CancerActive, not recruitingNCT06693128Lead sponsorPhase 2Start 2024-11
  15. Effect of a Self-designed MET Exercise Intervention on Cancer-related Fatigue in Patients With Gastric CancerCompletedNCT05401045Lead sponsorN/AStart 2023-01
  16. Lenvatinib With Taxane Drugs Treatment for Advanced Gastric CancerStatus unknownNCT05171530Lead sponsorPhase 1Start 2022-01
  17. Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node MetastasisStatus unknownNCT05002686Lead sponsorPhase 2/Phase 3Start 2021-08
  18. Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)Status unknownNCT04932187Lead sponsorPhase 1Start 2021-08
  19. Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric CancerStatus unknownNCT04781413Lead sponsorPhase 1/Phase 2Start 2021-03
  20. Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal MetastasisStatus unknownNCT05204173Lead sponsorPhase 2Start 2021-05
  21. In-hospital Outcomes of Older Patients With Gastric Cancer and Their Risk FactorsCompletedNCT06185907Lead sponsorStart 2021-04
  22. Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC)Status unknownNCT04410887Lead sponsorPhase 1/Phase 2Start 2020-12
  23. Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)Status unknownNCT04508686Lead sponsorPhase 1Start 2020-08
  24. ctDNA Screening in Advanced HER2 Positive Gastric CancerStatus unknownNCT04520295Lead sponsorStart 2020-05
  25. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Lead sponsorPhase 2/Phase 3Start 2019-12
  26. Development and Validation of the Surgical Assessment and Healthcare (SAH) Index for Gastric Cancer Treatment EvaluationCompletedNCT07180966Lead sponsorStart 2019-01
  27. Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric CancerCompletedNCT03636893Lead sponsorPhase 2Start 2018-08
  28. mFLOT Chemotherapy as First-line Treatment in GCCompletedNCT03606928Lead sponsorPhase 1/Phase 2Start 2018-07
  29. Feasibility and Safety of Neoadjuvant Chemotherapy (FLOT ) for Gastric Cancer Patients in ChinaCompletedNCT03646591Lead sponsorStart 2017-11
  30. Escorting Octogenarian for Gastric Cancer SurgeryCompletedNCT03639792Lead sponsorStart 2016-01
  31. Early Detection of Postoperative Anastomotic Leak by CTCompletedNCT03632395Lead (inferred)Start 2015-11
  32. Prospective Assessment of Alignment Between Multimodal Artificial Intelligence and Multidisciplinary Team Decisions in Gastrointestinal OncologyNot yet recruitingNCT07746830Study siteStart 2026-08
  33. Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer:MetBio-GCRecruitingNCT07076979Study siteStart 2025-06
  34. A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerRecruitingNCT06901531Study sitePhase 3Start 2025-05
  35. Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer:MetBio-CRCRecruitingNCT07068529Study siteStart 2025-06
  36. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  37. Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled StudyRecruitingNCT06679244Study siteN/AStart 2024-12
  38. DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapyRecruitingNCT06221748Study sitePhase 2/Phase 3Start 2024-02
  39. Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT05918094Study sitePhase 3Start 2023-04
  40. AI Prediction of Gastric Cancer Response to Neoadjuvant ChemotherapyRecruitingNCT06035250Study siteStart 2023-09
  41. A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic CancerRecruitingNCT05365581Study sitePhase 1Start 2022-06
  42. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  43. Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX RegimenStatus unknownNCT06036745Study sitePhase 2Start 2022-07
  44. A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric CancerSuspendedNCT05101616Study sitePhase 1/Phase 2Start 2022-07
  45. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  46. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  47. Performing Laparoscopic Surgery for Colorectal and Gastric Cancer Outside the Primary Registered Medical InstitutionCompletedNCT04834661Study siteStart 2021-10
  48. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  49. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10
  50. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  51. Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GCStatus unknownNCT04638959Study siteStart 2019-09
  52. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric CancersStatus unknownNCT03468712Study siteN/AStart 2018-03
  53. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerCompletedNCT03694522Study sitePhase 2Start 2018-09
  54. Incidence of Pancreatic Fistula After Radical GastrectomyStatus unknownNCT03391687Study siteStart 2017-12
  55. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)TerminatedNCT03019588Study sitePhase 3Start 2017-02
  56. Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma SurgeryStatus unknownNCT02130752Study siteN/AStart 2014-10
  57. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04
  58. Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)Status unknownNCT01609309Study sitePhase 3Start 2012-09

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 13 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
13
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 5520222023: 2220232024: 0020242025: 222025

60 hospitals in Shanghai for osteosarcoma742 hospitals in China for osteosarcoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT06114225

    Age 10 years to 65 years (registered criteria)

    Led by Ruijin HospitalShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiation oncologyPathology / laboratory medicineRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Papers it led13
  1. Stereotactic Body Radiation Therapy Augmented Checkpoint Inhibitor Immunotherapy Response in Heavily Pretreated Metastatic Osteosarcoma.2026International journal of radiation oncology, biology, physics
  2. Chemotherapeutic drug-triggered AEP-cleaved G3BP1 orchestrates stress granules/nucleoli/mitochondria in osteosarcoma.2025Bone research
  3. Enhanced antitumor immunity of VNP20009-CCL2-CXCL9 via the cGAS/STING axis in osteosarcoma lung metastasis.2025Journal for immunotherapy of cancer
  4. Spectral computed tomography-guided radiotherapy of osteosarcoma utilizing BiOI nanosheets.2023Acta biomaterialia
  5. Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma.2023Journal of cancer research and clinical oncology
  6. Thrombospondin-1 induced programmed death-ligand 1-mediated immunosuppression by activating the STAT3 pathway in osteosarcoma.2022Cancer science
  7. Vessel state and immune infiltration of the angiogenesis subgroup and construction of a prediction model in osteosarcoma.2022Frontiers in immunology
  8. Superenhancers activate the autophagy-related genes Beclin1 and LC3B to drive metastasis and drug resistance in osteosarcoma.2022Frontiers of medicine
  9. DNA Base Pairing-Inspired Supramolecular Nanodrug Camouflaged by Cancer-Cell Membrane for Osteosarcoma Treatment.2022Small (Weinheim an der Bergstrasse, Germany)
  10. Current Status and Prospects of Clinical Treatment of Osteosarcoma.2022Technology in cancer research & treatment
  11. Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma.2021Cell death & disease
  12. Development and analysis of long non-coding RNA-associated competing endogenous RNA network for osteosarcoma metastasis.2021Hereditas
  13. Peritumoral Microgel Reservoir for Long-Term Light-Controlled Triple-Synergistic Treatment of Osteosarcoma with Single Ultra-Low Dose.2021Small (Weinheim an der Bergstrasse, Germany)
Chinese-language papers (not in the count)1
  1. [Extraosseous Ewing's sarcoma of the pancreas: a clinicopathological analysis of 3 cases].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
Earlier papers (2016–2020)15
  1. MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma.2020Aging
  2. Isolation of extracellular vesicle with different precipitation-based methods exerts a tremendous impact on the biomarker analysis for clinical plasma samples.2020Cancer biomarkers : section A of Disease markers
  3. Establishment of a dynamic osteosarcoma biobank: Ruijin experience.2020Cell and tissue banking
  4. Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma.2019Journal of immunotherapy (Hagerstown, Md. : 1997)
  5. Pre-Operative chemotherapy response assessed by contrast-enhanced MRI can predict the prognosis of Enneking surgical margins in patients with osteosarcoma.2019Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  6. ASO Author Reflections: Metastatic Biopsy of Osteosarcoma with Circulating RNA.2018Annals of surgical oncology
  7. Extracellular Vesicle RNA Sequencing Reveals Dramatic Transcriptomic Alterations Between Metastatic and Primary Osteosarcoma in a Liquid Biopsy Approach.2018Annals of surgical oncology
  8. Exosomal miR-675 from metastatic osteosarcoma promotes cell migration and invasion by targeting CALN1.2018Biochemical and biophysical research communications
  9. Adaptive Fibrogenic Reprogramming of Osteosarcoma Stem Cells Promotes Metastatic Growth.2018Cell reports
  10. Bone tumors developed in patients with juvenile inflammatory arthritis after anti-TNFα therapy.2018Immunotherapy
  11. Primary, cardiac, fibroblastic osteosarcoma: A case report.2018Medicine
  12. Patellar height influences knee function in patients with aggressive bone tumors of the proximal tibia after endoprosthetic reconstruction.2018The Knee
  13. Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma in vitro and in vivo.2017Cancer science
  14. Rare Ileal Ewing Sarcoma/Primitive Neuroectodermal Tumor on 18F-FDG PET/CT.2017Clinical nuclear medicine
  15. Effects of resection margins on local recurrence of osteosarcoma in extremity and pelvis: Systematic review and meta-analysis.2016International journal of surgery (London, England)
All its trials on ClinicalTrials.gov, any status5
  1. Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical TrialRecruitingNCT06114225Lead sponsorPhase 2Start 2023-06
  2. Construction of Microfluidic Exosome Chip for Diagnosis of Lung Metastasis of OsteosarcomaCompletedNCT05101655Lead sponsorStart 2020-10
  3. Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapyStatus unknownNCT03742193Lead sponsorPhase 2Start 2019-08
  4. Circulating Exosome RNA in Lung Metastases of Primary High-Grade OsteosarcomaStatus unknownNCT03108677Lead sponsorStart 2017-05
  5. A Study of Sulfatinib on Relapsed or Refractory Drug Resistant OsteosarcomaNot yet recruitingNCT05590572Study sitePhase 1/Phase 2Start 2023-01

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 2 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

21 hospitals in Shanghai for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrologyGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)
Papers it led2
  1. A combined radiomic model distinguishing GISTs from leiomyomas and schwannomas in the stomach based on endoscopic ultrasonography images.2023Journal of applied clinical medical physicsFree full text
  2. Clinical characteristics and outcomes of gastrointestinal stromal tumor patients receiving surgery with or without TKI therapy: a retrospective real-world study.2023World journal of surgical oncology
Chinese-language papers (not in the count)1
  1. [Thrombotic microangiopathy caused by tyrosine kinase inhibitor in small intestine stromal tumor: a case report].2025Zhonghua nei ke za zhi
Earlier papers (2016–2020)5
  1. [Analysis and comparison of the clinical features and prognosis between extra - gastrointestinal stromal tumors and duodenal gastrointestinal stromal tumors].2019Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Analysis of clinical features and prognostic factors on reoperation patients with postoperative recurrence or metastasis of gastrointestinal stromal tumor].2018Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. Identifying therapeutic targets in gastric cancer: the current status and future direction.2016Acta biochimica et biophysica Sinica
  4. Facilitating retroflexed endoscopic full-thickness resection through loop-mediated or rope-mediated countertraction (with videos).2016Gastrointestinal endoscopy
  5. Comparison of the post-operative outcomes and survival of laparoscopic versus open resections for gastric gastrointestinal stromal tumors: A multi-center prospective cohort study.2016International journal of surgery (London, England)

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

34 hospitals in Shanghai for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

15 hospitals in Shanghai for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Chinese-language papers (not in the count)1
  1. [Extraosseous Ewing's sarcoma of the pancreas: a clinicopathological analysis of 3 cases].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
Earlier papers (2016–2020)1
  1. Rare Ileal Ewing Sarcoma/Primitive Neuroectodermal Tumor on 18F-FDG PET/CT.2017Clinical nuclear medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 22 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.3%.

Papers led
22
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 3320232024: 6620242025: 10102025

16 hospitals in Shanghai for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
    Phase
    Phase 1
    Started
    2026-09
    Registry
    NCT07914556

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  2. Recruiting
    A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2025-12
    Registry
    NCT07294625

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 4 listed hospitals as study sitesNanjing, Shanghai, Xi'an, Xuzhou, Zhengzhou

  3. Recruiting
    A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
    Phase
    Phase 1
    Started
    2023-03
    Registry
    NCT05759793

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  4. Recruiting
    A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
    Phase
    Phase 4
    Started
    2022-03
    Registry
    NCT05201781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an

  5. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesCAR-T & cell therapyDiagnosis, MRD & riskRelapse & resistance
Departments in papersRadiology / nuclear medicine
Papers it led22
  1. Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma.2026Chinese medical journalFree full text
  2. Targeting the HuR/E2F7 axis synergizes with bortezomib against multiple myeloma.2025Acta pharmacologica SinicaFree full text
  3. Therapy related acute myeloid leukemia secondary to CAR-T therapy in refractory/relapsed multiple myeloma patient showing poor prognosis.2025Annals of hematologyFree full text
  4. Exploring secondary extramedullary myeloma disease: a five-predictor scoring system with spotlight on double-hit cytogenetics.2025BMC medicineFree full text
  5. Targeting the RBM39-MEK5 axis synergizes with bortezomib to inhibit the malignant growth of multiple myeloma.2025Blood advancesFree full text
  6. Interleukin-5 is an adjunctive biomarker for engraftment syndrome in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation.2025Clinical immunology (Orlando, Fla.)
  7. Challenges facing CAR T-cell immunotherapy in multiple myeloma.2025Critical reviews in oncology/hematology
  8. Prognostic value of [18F]fluorodeoxyglucose-PET/MRI(CT) novel interpretation criteria (IMPeTUs) in multiple myeloma.2025European journal of nuclear medicine and molecular imaging
  9. Case Report: BCMA-targeting CAR T-cell therapy induces complete and durable remission in relapsed extramedullary plasmablastic multiple myeloma.2025Frontiers in immunologyFree full text
  10. Myeloma cell-intrinsic ANXA1 elevation and T cell dysfunction contribute to BCMA-negative relapse after CAR-T therapy.2025Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  11. Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma.2025Scientific reportsRCTFree full text
  12. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.2024BMC cancerFree full text
  13. PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion.2024Journal for immunotherapy of cancerFree full text
  14. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.2024Journal of hematology & oncologyFree full text
  15. Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma.2024Nature communicationsFree full text
  16. Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A.2024PloS oneFree full text
  17. Integrative analysis of an endoplasmic reticulum stress-related signature in multiple myeloma.2024The journal of gene medicine
  18. Re: CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor-T-cell therapy in multiple myeloma.2023European journal of cancer (Oxford, England : 1990)
  19. Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).2023Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  20. Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity.2023Signal transduction and targeted therapyFree full text
  21. SPAG5 as a novel biomarker and potential therapeutic target via regulating AKT pathway in multiple myeloma.2022Leukemia & lymphoma
  22. Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance.2021British journal of cancerFree full text
Chinese-language papers (not in the count)7
  1. [Characteristics and Risk Analysis of COVID-19 Infection in Patients with Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation].2025Zhongguo shi yan xue ye xue za zhi
  2. [Effect of different induction chemotherapy regimens on autologous hematopoietic stem cell mobilization in patients with multiple myeloma in the new drug era].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  3. [Research progress on targeted delivery of proteasome inhibitor nanoparticles for the treatment of multiple myeloma].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  4. [Research progress in targeting GPRC5D for the treatment of multiple myeloma].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  5. [Effects of extramedullary disease on patients with newly diagnosed multiple myeloma].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  6. [Efficiency and safety analysis of Plerixafor combined with granulocyte colony-stimulating factor on autologous hematopoietic stem cell mobilization in lymphoma].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  7. [Clinical characteristics and prognosis of patients with newly-diagnosed multiple myeloma with t(11;14)].2022Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status23
  1. Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma PatientsTerminatedNCT00984828Lead (inferred)Phase 2/Phase 3Start 2009-08
  2. Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for MyelomaSuspendedNCT00892346Lead (inferred)Phase 3Start 2009-05
  3. Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood CancersRecruitingNCT07914556Study sitePhase 1Start 2026-09
  4. A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT07294625Study siteEarly phase 1Start 2025-12
  5. A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaRecruitingNCT05759793Study sitePhase 1Start 2023-03
  6. A Long-term Study for Participants Previously Treated With Ciltacabtagene AutoleucelRecruitingNCT05201781Study sitePhase 4Start 2022-03
  7. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  8. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01
  9. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  10. A Study of DaratumumabActive, not recruitingNCT05438043Study sitePhase 3Start 2022-12
  11. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  12. A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory MyelomaTerminatedNCT04735575Study sitePhase 1/Phase 2Start 2021-05
  13. A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple MyelomaStatus unknownNCT05271682Study sitePhase 1Start 2021-12
  14. A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)Status unknownNCT05066646Study sitePhase 1/Phase 2Start 2020-04
  15. A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT03758417Study sitePhase 2Start 2019-01
  16. Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)CompletedNCT03748953Study sitePhase 3Start 2019-01
  17. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03
  18. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Active, not recruitingNCT03539744Study sitePhase 3Start 2018-10
  19. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  20. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Study sitePhase 3Start 2017-11
  21. A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)CompletedNCT02312258Study sitePhase 3Start 2015-04
  22. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple MyelomaCompletedNCT01818752Study sitePhase 3Start 2013-07
  23. Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple MyelomaCompletedNCT00689936Study sitePhase 3Start 2008-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 11 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 4.9%.

Papers led
11
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
4
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 0020222023: 2220232024: 3320242025: 332025

9 hospitals in Shanghai for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07838714

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  2. Recruiting
    Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06718244

    Age 16 years to 70 years (registered criteria)

    Led by Ruijin HospitalShanghai

  3. Not yet recruiting
    Ex Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute Leukemia
    Phase
    N/A
    Started
    2025-09
    Registry
    NCT07087847

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  4. Not yet recruiting
    BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07301138

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  5. Not yet recruiting
    Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL
    Phase
    Phase 1
    Started
    2024-11
    Registry
    NCT06641024

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPhiladelphia chromosome & geneticsAntibody & targeted drugsStem cell transplant
Papers it led11
  1. Resolving Leukemia Heterogeneity and Lineage Aberrations with HematoMap.2025Genomics, proteomics & bioinformaticsFree full text
  2. Differences in response to immunotherapy drugs including blinatumomab and inotuzumab ozogamicin in B-ALL patients.2025International journal of hematology
  3. Targeting HDAC8 sensitizes tyrosine kinase inhibitors in the elimination of B-cell acute lymphoblastic leukemia cells through degradation of HIF-1α.2025Leukemia
  4. BCR::ABL1-Like B-Cell Acute Lymphoblastic Leukemia with BCR::PDGFRA Fusion: A Case Report and Literature Review.2024Acta haematologica
  5. Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia/lymphoma following allogeneic hematopoietic cell transplantation.2024Blood cancer journalFree full text
  6. Integrative alternative splicing analysis reveals new prognosis signature in B-cell acute lymphoblastic leukemia.2024International journal of biological sciencesFree full text
  7. Transcription factor 12-mediated self-feedback regulatory mechanism is required in DUX4 fusion leukaemia.2023Clinical and translational medicineFree full text
  8. Transcription factor abnormalities in B-ALL leukemogenesis and treatment.2023Trends in cancer
  9. Therapeutic Potential of TNFα and IL1β Blockade for CRS/ICANS in CAR-T Therapy via Ameliorating Endothelial Activation.2021Frontiers in immunologyFree full text
  10. Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.2021Frontiers of medicine
  11. Purification, crystallization, and X-ray diffraction analysis of myocyte enhancer factor 2D and DNA complex.2021Protein expression and purification
Chinese-language papers (not in the count)1
  1. [Clinical analysis of 16 cases of adult acute B-lymphoblastic leukemia treated with blinatumomab].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status8
  1. Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic LeukemiaRecruitingNCT07838714Lead sponsorPhase 1Start 2026-05
  2. BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia PatientsNot yet recruitingNCT07301138Lead sponsorPhase 2Start 2025-12
  3. Ex Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute LeukemiaNot yet recruitingNCT07087847Lead sponsorN/AStart 2025-09
  4. Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1RecruitingNCT06718244Lead sponsorPhase 2Start 2024-12
  5. A Real-world Study on the Treatment of Adult B-cell Acute Lymphoblastic Leukemia With CNCT-19Active, not recruitingNCT07269587Lead sponsorStart 2025-11
  6. A Multi-center Retrospective Study of INO Treating B-ALLActive, not recruitingNCT07238907Lead sponsorStart 2022-06
  7. Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALLNot yet recruitingNCT06641024Study sitePhase 1Start 2024-11
  8. To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.Status unknownNCT05223686Study sitePhase 1Start 2022-02

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

5 hospitals in Shanghai for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesTreatment regimensEBV & infection triggersLymphoma & cancer-related HLH
Departments in papersRheumatology & immunology
Papers it led2
  1. Ruxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndrome.2025BloodFree full text
  2. Risk factors for secondary hemophagocytic lymphohistiocytosis in severe coronavirus disease 2019 adult patients.2021BMC infectious diseasesFree full text
Chinese-language papers (not in the count)1
  1. [Clinical features and risk factors for secondary hemophagocytic lymphohistiocytosis in elderly patients with severe SARS-CoV-2 infection: a multicenter retrospective cohort study].2023Zhonghua wei zhong bing ji jiu yi xue
All its trials on ClinicalTrials.gov, any status1
  1. A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))CompletedNCT07034209Study sitePhase 2Start 2023-04
More papers found outside PubMed (not counted)5
  1. POS0387 NEUTROPHIL EXTRACELLULAR TRAPS ACCELERATE CYTOKINE STORM IN AUTOIMMUNE AND AUTOINFLAMMATORY DISEASE BY PROMOTING STING-MEDIATED MYELOPOIEIS2025Annals of the Rheumatic Diseasesconference-abstract
  2. POS1430 GENETIC LANDSCAPE OF ADULT-ONSET STILL'S DISEASE WITH MACROPHAGE ACTIVATION SYNDROME: IDENTIFYING KEY RISK LOCI FOR DISEASE MECHANISMS AND PERSONALIZED TREATMENT2025Annals of the Rheumatic Diseasesconference-abstract
  3. Ruxolitinib concentrations in cerebrospinal fluid in patients with hemophagocytic lymphohistiocytosis and potential significance of central nervous system involvement2025Bloodconference-abstract
  4. The prospect of high-dose vitamin c in improving early survival in patients with hemophagocytic lymphohistiocytosis2025Bloodconference-abstract
  5. Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up2022Bloodarticle

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution

7 hospitals in Shanghai for beta thalassaemia157 hospitals in China for beta thalassaemia

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    β-Thalassemia Treatment With KL003 Cell Injection
    Phase
    Phase 1/Phase 2
    Started
    2024-04
    Registry
    NCT06280378

    Age 3 years to 35 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Tianjin

  2. Recruiting
    A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
    Phase
    Phase 1
    Started
    2024-01
    Registry
    NCT06465550

    Age 3 years to 35 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Nanning, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Chinese-language papers (not in the count)1
  1. [Study of the types of mutations of Thalassemia in Shanghai area].2024Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
All its trials on ClinicalTrials.gov, any status5
  1. A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia MajorRecruitingNCT06465550Study sitePhase 1Start 2024-01
  2. β-Thalassemia Treatment With KL003 Cell InjectionRecruitingNCT06280378Study sitePhase 1/Phase 2Start 2024-04
  3. A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia MajorNot yet recruitingNCT07489196Study sitePhase 2Start 2026-04
  4. A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia MajorCompletedNCT06291961Study sitePhase 1Start 2024-04
  5. Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemiaStatus unknownNCT05776173Study siteN/AStart 2023-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 5 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 1.8%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 0020242025: 112025

9 hospitals in Shanghai for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led5
  1. Single-cell sequencing on PBMCs from patients with HA and HB with inhibitors reveals different immune responses to FVIII and FIX.2025Blood advances
  2. Tandem and inverted duplications in haemophilia A: Breakpoint characterisation provides insight into possible rearrangement mechanisms.2023Haemophilia : the official journal of the World Federation of Hemophilia
  3. Long-term correction of hemorrhagic diathesis in hemophilia A mice by an AAV-delivered hybrid FVIII composed of the human heavy chain and the rat light chain.2022Frontiers of medicine
  4. Characteristics of the Thrombus Formation in Transgenic Mice with Platelet-Targeted Factor VIII Expression.2022Thrombosis and haemostasis
  5. Activated factor X targeted stored in platelets as an effective gene therapy strategy for both hemophilia A and B.2021Clinical and translational medicine
Chinese-language papers (not in the count)1
  1. [Perioperative management of a patient with hemophilia a and high-titer inhibitors and literature review].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Earlier papers (2016–2020)11
  1. Maternal microchimerism protects hemophilia A patients from inhibitor development.2020Blood advances
  2. In vivo generated hematopoietic stem cells from genome edited induced pluripotent stem cells are functional in platelet-targeted gene therapy of murine hemophilia A.2020Haematologica
  3. [A case of acquired hemophilia A with multiple superficial blistering skin disorders as the main manifestation].2020Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  4. [Optimized AAV package and experimental application of recombinant AAV8/hFⅧ for gene therapy on hemophilia A mice].2020Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  5. Low factor V level ameliorates bleeding diathesis in patients with combined deficiency of factor V and factor VIII.2019Blood
  6. Inhibitor eradication and bleeding management of acquired hemophilia A: a single center experience in China.2019Hematology (Amsterdam, Netherlands)
  7. Evaluation of the activity levels of rat FVIII and human FVIII delivered by adeno-associated viral vectors both in vitro and in vivo.2018Blood cells, molecules & diseases
  8. Spectrum and origin of mutations in sporadic cases of haemophilia A in China.2018Haemophilia : the official journal of the World Federation of Hemophilia
  9. Complex recombination with deletion in the F8 and duplication in the TMLHE mediated by int22h copies during early embryogenesis.2017Thrombosis and haemostasis
  10. AccuCopy quantification combined with pre-amplification of long-distance PCR for fast analysis of intron 22 inversion in haemophilia A.2016Clinica chimica acta; international journal of clinical chemistry
  11. Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment.2016Gene therapy
All its trials on ClinicalTrials.gov, any status8
  1. Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCompletedNCT06738485Study sitePhase 3Start 2025-01
  2. Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with InhibitorCompletedNCT06289166Study sitePhase 2Start 2024-03
  3. An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII DeficiencyRecruitingNCT07644832Study sitePhase 1/Phase 2Start 2024-05
  4. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinCompletedNCT06142552Study sitePhase 3Start 2023-12
  5. Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A ParticipantsCompletedNCT03315455Study sitePhase 3Start 2018-04
  6. Evaluate Efficacy and Safety of Recombinant Factor VIII (rFVIII)Treatment of Severe or Moderately Severe Hemophilia AStatus unknownNCT02930317Study sitePhase 3Start 2016-08
  7. PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia ACompletedNCT02492984Study sitePhase 4Start 2015-04
  8. China ADVATE PTP StudyCompletedNCT02170402Study sitePhase 4Start 2014-06

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led no English-language PubMed papers on thrombotic thrombocytopenic purpura in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Shanghai for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)Status unknownNCT04021173Study sitePhase 2Start 2019-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 2 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

4 hospitals in Shanghai for moyamoya disease47 hospitals in China for moyamoya disease

No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & blood flowRevascularisation surgeryStroke & bleeding outcomes
Departments in papersNeurosurgeryNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 1 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

9 hospitals in Shanghai for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

34 hospitals in Shanghai for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led 2 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 4.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Shanghai for lymphangioleiomyomatosis28 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 2 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

17 hospitals in Shanghai for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Shanghai for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 3 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 4.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

6 hospitals in Shanghai for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrologyOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led 1 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

5 hospitals in Shanghai for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Papers it led1
  1. Tauroursodeoxycholic acid ameliorates renal injury induced by COL4A3 mutation.2024Kidney international
Earlier papers (2016–2020)1
  1. [Advances in research on gene and cell therapy for type IV collagen related hereditary kidney diseases].2019Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 4 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.5%.

Papers led
4
2021–2025
Trials led
7
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

26 hospitals in Shanghai for IgA nephropathy346 hospitals in China for IgA nephropathy

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of Telitacicept in IgAN
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06654596

    Age 18 years to 70 years (registered criteria)

    Led by Ruijin HospitalShanghai

  2. Recruiting
    The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
    Phase
    Not given
    Started
    2020-12
    Registry
    NCT04858724

    Age not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  3. Recruiting
    A Study of SHR-2173 in Participants With Primary IgA Nephropathy
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07354932

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  4. Recruiting
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    Phase
    Phase 3
    Started
    2025-07
    Registry
    NCT06963827

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrology
Papers it led4
  1. Thickening of Glomerular Basement Membrane Is Associated with Long-Term Prognosis in Patients with IgA Nephropathy.2026Kidney360
  2. Uncovering Rare Coding Variants in IgA Nephropathy.2023Journal of the American Society of Nephrology : JASN
  3. Particulate matter of air pollution may increase risk of kidney failure in IgA nephropathy.2022Kidney international
  4. A Validation Study Comparing Risk Prediction Models of IgA Nephropathy.2021Frontiers in immunology
Earlier papers (2016–2020)9
  1. A Rare Genetic Defect of MBL2 Increased the Risk for Progression of IgA Nephropathy.2019Frontiers in immunologyRCT
  2. Kidney Failure Risk Prediction Equations in IgA Nephropathy: A Multicenter Risk Assessment Study in Chinese Patients.2018American journal of kidney diseases : the official journal of the National Kidney Foundation
  3. IgA Nephropathy Susceptibility Loci and Disease Progression.2018Clinical journal of the American Society of Nephrology : CJASN
  4. A validation study of crescents in predicting ESRD in patients with IgA nephropathy.2018Journal of translational medicine
  5. [The clinicopathological characteristics of diabetic nephropathy and non-diabetic renal diseases in diabetic patients].2017Zhonghua nei ke za zhi
  6. Histone deacetylase inhibitors attenuate P-aIgA1-induced cell proliferation and extracellular matrix synthesis in human renal mesangial cells in vitro.2016Acta pharmacologica Sinica
  7. Fine Mapping Implicates a Deletion of CFHR1 and CFHR3 in Protection from IgA Nephropathy in Han Chinese.2016Journal of the American Society of Nephrology : JASN
  8. Bilateral Posterior Scleritis Presenting as the First Manifestation of Immunoglobulin A Nephropathy: Case Report and Review of the Literature.2016Ocular immunology and inflammation
  9. Underweight Is an Independent Risk Factor for Renal Function Deterioration in Patients with IgA Nephropathy.2016PloS one
All its trials on ClinicalTrials.gov, any status13
  1. Efficacy and Safety of Telitacicept in IgANRecruitingNCT06654596Lead sponsorN/AStart 2024-12
  2. The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)RecruitingNCT04858724Lead sponsorStart 2020-12
  3. Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological LesionsNot yet recruitingNCT07888335Lead sponsorPhase 4Start 2026-12
  4. Replication of the NefIgArd Trial of TRF-budesonide in Primary IgANCompletedNCT06589752Lead sponsorStart 2023-04
  5. Bortezomib for Treating Glomerular DiseasesStatus unknownNCT05383547Lead sponsorN/AStart 2022-08
  6. Rituximab and RASi in Patients with IgANCompletedNCT04525729Lead (inferred)Phase 4Start 2020-07
  7. A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA NephropathyStatus unknownNCT05824390Lead (inferred)Phase 4Start 2020-06
  8. A Study of SHR-2173 in Participants With Primary IgA NephropathyRecruitingNCT07354932Study sitePhase 2Start 2026-03
  9. A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyRecruitingNCT06963827Study sitePhase 3Start 2025-07
  10. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune DiseasesNot yet recruitingNCT06774664Study sitePhase 1/Phase 2Start 2025-01
  11. A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of ProgressionActive, not recruitingNCT05797610Study sitePhase 3Start 2023-08
  12. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  13. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

17 hospitals in Shanghai for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 2 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 3.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

9 hospitals in Shanghai for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

上海交通大学医学院附属瑞金医院

Ruijin Hospital

上海

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Rui-Jin Hospital; Rui Jin Hospital; Ruijin Hospital North; Wuxi Branch of Ruijin Hospital; Rui Jin Hospital affiliated with Shanghai Jiaotong University; Ruijin Hospital/Lu Wan Branch; RuiJin Hospital; Medical Center on Aging of Ruijin Hospital

Suggest a correctionDownload the data